Review
. 2008 Jul;17(7 Suppl 7):9-12; discussion 17-8.
Assessing therapeutically developed assays
Affiliations
- PMID: 19097282
Item in Clipboard
Review
Assessing therapeutically developed assays
Manag Care.
2008 Jul.
Abstract
Risk classification of early-stage breast cancer patients by gene expression profiling can result in substantial drug cost savings. Economic analyses suggest that appropriate use of clinically validated molecular diagnostics offers the potential for cost savings and improved patient quality of life.
Similar articles
-
A health plan's integration of molecular diagnostics and the impact on treatment pathways for quality care.Manag Care. 2008 Jul;17(7 Suppl 7):13-6; discussion 17-8. Manag Care. 2008. PMID: 19093337
-
Quantitative biology: a new paradigm for tumor profiling, prognosis, and treatment.Manag Care. 2008 Jul;17(7 Suppl 7):3; discussion 17-8. Manag Care. 2008. PMID: 19097281 No abstract available.
-
Understanding tumor profiling and assessing treatment.Manag Care. 2008 Jul;17(7 Suppl 7):4-8; discussion 17-8. Manag Care. 2008. PMID: 19093336 Review.
-
Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.Cancer Invest. 2009 Dec;27(10):953-9. doi: 10.3109/07357900903275217. Cancer Invest. 2009. PMID: 19909009 No abstract available.
-
Adjuvant chemotherapy for early-stage breast cancer.Hematol Oncol Clin North Am. 2007 Apr;21(2):207-22. doi: 10.1016/j.hoc.2007.03.008. Hematol Oncol Clin North Am. 2007. PMID: 17512445 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical